Differences in the prescription patterns of anti-asthmatic medications for children by pediatricians, family physicians and physicians of other specialties

Journal of the Formosan Medical Association

Volumn 105, Issue 4, 2006, Pages 277-283

  Sun, Hai Lun ^a,b   Kao, Yea Huei ^c   Chou, Ming Chieh ^b   Lu, Tsung Hsueh ^b   Lue, Ko Huang ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Asthma; Family medicine; Insurance claims; Pediatrics; Prescription

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; XANTHINE DERIVATIVE;

ARTICLE; ASTHMA; CHILD HEALTH CARE; CONTROLLED STUDY; GENERAL PRACTITIONER; HUMAN; MEDICAL SPECIALIST; MONOTHERAPY; NATIONAL HEALTH INSURANCE; PEDIATRICIAN; PHYSICIAN ATTITUDE; PRESCRIPTION; TREATMENT OUTCOME;

EID: 33645318984     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(09)60118-2     Document Type: Article

References (26)

1. Masoli M, Fabian D, Holt S, et al. Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-78.
2. Blumenthal M, Bousquet J. Evidence for an increase in atopic disease and possible causes. Clin Exp Allergy 1993; 23:484-92.
3. Hsieh KH, Shen JJ. Prevalence of childhood asthma in Taipei, Taiwan, and other Asian Pacific countries. J Asthma 1988;25:73-82.
4. Wang WC, Lue KH, Sheu JN. Allergic diseases in preschool children in Taichung City. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1998;39:314-8.
5. Global Initiative for Asthma. National Heart, Lung and Blood Institute, (US)/World Health Organization, 1995 January (revised 1998).
6. Grant EN, Moy JN, Turner-Roan K, et al. Asthma care practices, perceptions, and beliefs of Chicago-area primary-care physicians. Chest 1999;116:145S-54S.
7. Buchner DA, Carlson AM, Stempel DA. Patterns of antiinflammatory therapy in the post-guidelines era: a retrospective claims analysis of managed care members. Am J Manag Care 1997;3:87-93.
8. Goodman DC, Lozano P, Stukel TA, et al. Has asthma medication use in children become more frequent, more appropriate, or both? Pediatrics 1999;104:187-94A.
9. Weinberger M, Hendeles L. Theophylline use: an overview. J Allergy Clin Immunol 1985;76:277-84.
10. Weinberger M, Hendeles L. Experience with theophylline for the management of chronic asthma. Eur J Respir Dis Suppl 1980;109:120-33.
11. Weinberger MM. Theophylline QID, TID, BID and now QD? Pharmacotherapy 1984;4:181-8.
12. Holimon TD, Chafin CC, Self TH. Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2-agonists? Drugs 2001;61:391-418.
13. Eggleston PA, Malveaux FJ, Butz AM, et al. Medications used by children with asthma living in the inner city. Pediatrics 1998;101:349-54.
14. Lozano P, Sullivan SD, Smith DH, et al. The economic burden of asthma in US children: estimates from the National Medical Expenditure Survey. J Allergy Clin Immunol 1999;104:957-63.
15. Halterman JS, Aligne CA, Auinger P, et al. Inadequate therapy for asthma among children in the United States. Pediatrics 2000;105:272-6.
16. Beimfohr C, Maziak W, von Mutius E, et al. The use of anti-asthmatic drugs in children: results of a community-based survey in Germany. Pharmacoepidemiol Drug Saf 2001; 10:315-21.
17. Warner JO. Review of prescribed treatment for children with asthma in 1990. Br Med J 1995;311:663-6.
18. Adams RJ, Fuhlbrigge A, Finkelstein, et al. Use of inhaled anti-inflammatory medication with asthma in managed care setting. Arch Pediatr Adolesc Med 2001;155:501-7.
19. Chen CY, Chiu HF, Yeh MK, et al. The use of anti-asthmatic medications among pediatric patients in Taiwan. Pharmacoepidemiol Drug Saf 2003;12:129-33.
20. Eggleston PA. Are beta-adrenergic bronchodilators safe? Pediatrics 1997;99:729-30.
21. Ernst P, Hemmelgarn B, Cockcroft DW. Overreliance on bronchodilators as a risk factor for life-threatening asthma. Can Respir J 1995;2:1316-21.
22. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6.
23. Simons FER, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997;99:655-9.
24. Kemp JP, Dockhorn RJ, Busse WW. Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Am J Respir Crit Care Med 1994;150:1612-5.
25. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br Med J 2000;320:1368-73.
26. Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta2-agonist monotherapy vs. continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001;285:2583-93.